These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 34305910)

  • 1. Immune Checkpoint Inhibitors in Human Glioma Microenvironment.
    Ghouzlani A; Kandoussi S; Tall M; Reddy KP; Rafii S; Badou A
    Front Immunol; 2021; 12():679425. PubMed ID: 34305910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes.
    Qi Y; Liu B; Sun Q; Xiong X; Chen Q
    Front Immunol; 2020; 11():578877. PubMed ID: 33329549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
    Chen R; Cohen AL; Colman H
    Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
    Zhang N; Wei L; Ye M; Kang C; You H
    Front Immunol; 2020; 11():592612. PubMed ID: 33329578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas.
    Chen R; Wang X; Dai Z; Wang Z; Wu W; Hu Z; Zhang X; Liu Z; Zhang H; Cheng Q
    Front Immunol; 2021; 12():713757. PubMed ID: 34712225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory Effects of Tryptophan Metabolism in the Glioma Tumor Microenvironment.
    Xu Y; Zhang H; Sun Q; Geng R; Yuan F; Liu B; Chen Q
    Front Immunol; 2021; 12():730289. PubMed ID: 34659216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.
    Ghouzlani A; Lakhdar A; Rafii S; Karkouri M; Badou A
    Sci Rep; 2021 Nov; 11(1):21504. PubMed ID: 34728682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
    Inocencio JF; Mitrasinovic S; Asad M; Parney IF; Zang X; Himes BT
    Front Immunol; 2024; 15():1424396. PubMed ID: 39346924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma.
    Foster A; Nigam S; Tatum DS; Raphael I; Xu J; Kumar R; Plakseychuk E; Latoche JD; Vincze S; Li B; Giri R; McCarl LH; Edinger R; Ak M; Peddagangireddy V; Foley LM; Hitchens TK; Colen RR; Pollack IF; Panigrahy A; Magda D; Anderson CJ; Edwards WB; Kohanbash G
    EBioMedicine; 2021 Sep; 71():103571. PubMed ID: 34530385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
    Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
    Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas.
    Bockmayr M; Klauschen F; Maire CL; Rutkowski S; Westphal M; Lamszus K; Schüller U; Mohme M
    Cancer Immunol Res; 2019 Sep; 7(9):1401-1411. PubMed ID: 31266783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour immune landscape of paediatric high-grade gliomas.
    Ross JL; Velazquez Vega J; Plant A; MacDonald TJ; Becher OJ; Hambardzumyan D
    Brain; 2021 Oct; 144(9):2594-2609. PubMed ID: 33856022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T lymphocyte-targeted immune checkpoint modulation in glioma.
    Kelly WJ; Giles AJ; Gilbert M
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.
    Arrieta VA; Dmello C; McGrail DJ; Brat DJ; Lee-Chang C; Heimberger AB; Chand D; Stupp R; Sonabend AM
    J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
    Zhang QJ; Luan JC; Song LB; Cong R; Ji CJ; Zhou X; Xia JD; Song NH
    Front Immunol; 2021; 12():657575. PubMed ID: 33936087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
    Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
    Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.